TPST: מחיר רכישת החברה tempesttx.com
Financial quote visualization for Tempest Therapeutics (TPST), which focuses on oncology therapies, shows an Enterprise Value of 15.40. To ensure test reliability, the company invests in costly temperature-controlled drug transportation. Its environmental development vector involves reducing harmful emissions during drug synthesis and maintaining an ethical approach to research. Stable management with deep expertise is preparing the business for collaboration with industry behemoths.
TPST (Tempest Therapeutics): פילוחים אנליטיים ודוחות לפי אינדיקטורים
The enterprise value of Tempest Therapeutics (TPST) reflects the total acquisition cost of the business, accounting for net debt. This EV chart aggregates market capitalization and liabilities, minus existing cash reserves. This metric allows for an assessment of the asset's real value beyond its equity. For a biotech firm with high R&D expenditures, this indicator is critical. The value trend highlights the company's financial vulnerability in the event of a potential failure of its oncology drug clinical trials.